Skip to content

The minimally invasive treatment of cholecystolithiasis combined with common bile duct stone between 0.6cm to 1cm: a multicentre randomized controlled trial

The minimally invasive treatment of cholecystolithiasis combined with common bile duct stone between 0.6cm to 1cm: a multicentre randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021283
Enrollment
Unknown
Registered
2019-02-11
Start date
2019-02-14
Completion date
Unknown
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholelithiasis

Interventions

A: Traditional two-steps group:ERCP for removing calculus + ENBD + LC
B: One-step group:LC + LCBDE + choledochoscope + one stage suture after CBD incision
C: New two-steps group:ERCP for examination + 6-8mm balloon dilatation +ENBD+LC+LCBDE+choledochoscope+one stage suture after CBD incision

Sponsors

The First Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Gallstones and CBD stones are indicated by image examinations; 2. CT or MRCP shows that the biggest CBD stone is between 0.6-1.0cm, diameter of CBD is <2.5cm; 3. General condition is fine without other organ diseases; 4. The ERCP or surgical indications are clear without contraindications (selective operation: cholelithiasis has been controlled over a month; emergency operation: cholangitis attack is in 72 hours); 5. No other treatments for biliary calculus before this study, such as ERCP or operations; 6. Aged 18 to 80 years; 7. Baseline laboratory examination: PLT=100×10^9/L, ALT or AST = 3 ×ULN; TBIL=85µmol/L; creatinine= 1.5 × ULN; INR < 1.5 or PT< ULN+4s; 8. Patients with good compliance can follow the protocol of the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute obstructive pyogenic cholangitis; 2. Combining with acute pancreatitis before operation; 3. Malignancy tumor of bile duct; 4. After subtotal gastrectomy; 5. After cholecystectomy; 6. Combining with intrahepatic duct stones indicated by imaging examinations; 7. Obvious stenosis of bile duct, immunity or sclerosing cholangitis; 8. HCG positive female or lactating female; 9. Cachexy or poor general conditions; 10. Have any conditions described below 12 months before study: myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting, CHF, stroke (including transient ischemic cerebrovascular disease), pulmonary embolism, in progress: arrhythmia over stage 2 in NCI-CTCAE, QT interval prolongation (male >450ms, female >470ms); 11. Have suffered from malignancy tumor in 5 years; 12. Renal insufficiency, which is treated with hemodialysis or peritoneal dialysis; 13. Other severe dysfunction of other organ; 14. Haemophilia or bleeding tendency with anticoagulant therapy; 15. Have had organ grafting; 16. HIV infection; 17. Nervous system disease; 18. Have other physiologically or nervous system diseases and abnormal condition of laboratory examination which can increase risks related to the study or disturb discussion of the study results.

Design outcomes

Primary

MeasureTime frame
Operative successful rate;

Secondary

MeasureTime frame
Early postoperative complications and death;Late postoperative complications;Total operation time;Opration time for ERCP;Time of laparoscope operation;Length of stay;Total cost;Postoperative pain score;Patients' satisfaction;Symptom of digestive tract;Function of Oddi's sphincter;

Countries

China

Contacts

Public ContactHua Yunpeng

The First Affiliated Hospital of Sun Yat-Sen University

hyp0427@163.com+86 13318835569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026